Merck to acquire Verona Pharma

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm’s respiratory treatment portfolio in a bid to diversify its revenue source beyond blockbuster cancer drug. Merck has been leaning on its aging cancer immunotherapy Keytruda, the world’s top-selling prescription medicine, which generated nearly $30 billion in…

Read More
Back To Top